Popular Trials
CAR T-cell Therapy
EBV-specific CTLs for Neuroblastoma
This trial is testing a new way to fight neuroblastoma, a form of cancer, by combining two different types of cells that each attack the disease in different ways. The new cell is made by attaching an antibody that recognizes neuroblastoma cells to a type of cell that normally fights infectious mononucleosis. This new cell is given to patients with neuroblastoma that has returned and is not responding to other treatments.
Virus Therapy
HLA-matched VSTs for Viral Infections Post Stem Cell Transplant
This trial is for patients who have had a stem cell transplant and have developed a viral infection that is not responding to standard therapy. In this trial, the patient will receive white blood cells that have been specially trained to fight the viral infection.
CAR T-cell Therapy
Adoptive Immunotherapy for Viral Infections
This trial is a Phase I-II dose-finding trial to determine the optimal dose of intravenous injection of donor-derived cytotoxic T lymphocytes specific for CMV, EBV, BKV, and Adenovirus.
CAR T-cell Therapy
Genetically Modified T cells for Leukemia and Lymphoma
This trial is testing the safety of giving patients modified T-cells from a donor. The goal is to see if these cells cause any toxicities in patients with relapsed B cell leukemia or lymphoma.
HDAC inhibitor
Nanatinostat + Valganciclovir/Pembrolizumab for Nasopharyngeal Cancer
This trial tests a combination of nanatinostat, valganciclovir, and pembrolizumab in patients with certain EBV-related cancers. Nanatinostat makes cancer cells more vulnerable, allowing valganciclovir to kill them, while pembrolizumab boosts the immune system to fight the cancer.
Popular Filters
Trials for Diffuse Large B-Cell Lymphoma Patients
CAR T-cell Therapy
T-cell Therapy for Lymphoma
This trial is testing a new way to fight cancer by combining two existing methods. Antibodies stick to cancer cells, and T cells are special infection-fighting blood cells that can kill other cells. The hope is that by combining these two methods, the cancer cells will be killed more effectively.
Trials for Follicular Lymphoma Patients
CAR T-cell Therapy
T-cell Therapy for Lymphoma
This trial is testing a new way to fight cancer by combining two existing methods. Antibodies stick to cancer cells, and T cells are special infection-fighting blood cells that can kill other cells. The hope is that by combining these two methods, the cancer cells will be killed more effectively.
Trials for EBV Positive Patients
Monoclonal Antibodies
Rituximab + LMP-Specific T-Cells for Post-transplant Lymphoproliferative Disease
This trial is testing if a combination of rituximab and LMP-specific T-cells is more effective than rituximab alone in treating pediatric patients with post-transplant lymphoproliferative disorder.
CAR T-cell Therapy
Cytotoxic T Cells for Lymphoma
This trial is testing whether a new experimental therapy, third party LMP specific cytotoxic T lymphocytes (CTLs), can prevent or treat EBV Disorder including either Hodgkin Lymphoma or non-Hodgkin Lymphoma or Lymphoepithelioma or severe chronic active EBV infection syndrome (SCAEBV) or Leiomyosarcoma which has come back or has not gone away after treatment, including the best treatment.
CAR T-cell Therapy
EBV-Specific Cytotoxic T-Lymphocytes for Lymphoma
This trial is for people with Hodgkin or non-Hodgkin lymphoma, T/NK-lymphoproliferative disease, or severe chronic active Epstein Barr Virus (CAEBV) that has come back or is at risk of coming back.
CAR T-cell Therapy
EBV-Specific T-Cell Therapy for Lymphoma
This trial is for patients with Hodgkin or non-Hodgkin lymphoma that has come back or has not gone away after treatment, who also show signs of Epstein Barr virus. T cells will be infused that have been genetically modified to target and kill cancer cells infected with EBV. The goal is to find the largest safe dose and evaluate how long the cells can be detected in the blood and what affect they have on cancer.
Trials With No Placebo
Monoclonal Antibodies
STAR0602 for Advanced Cancers
This trial is testing a new drug called STAR0602 to see if it is safe and effective for treating advanced cancers with specific markers. The drug is given through an IV and aims to find and destroy cancer cells by recognizing these markers. The study will first determine the best dose and then see how well the drug works in patients.
CAR T-cell Therapy
R-MVST Cells for Viral Infections
This trial is testing a cell therapy called R-MVST for safety and feasibility in patients with refractory viral reactivation and/or symptomatic disease caused by Epstein Barr Virus (EBV), cytomegalovirus (CMV), adenovirus (ADV) or BK virus. The cell therapy will be generated on-demand from the closest partially human leukocyte antigen (HLA)-matched (minimum haploidentical) healthy donors or from the original allo-transplant donor if available.
Alkylating agents
Chemotherapy and Radiation Based on EBV DNA for Nasopharyngeal Cancer
This trial tests different combinations of chemotherapy drugs and radiation therapy for advanced nasopharyngeal cancer. It targets patients whose cancer has not spread beyond the local region. The treatment works by killing cancer cells or stopping their growth using powerful drugs and radiation. Previous studies have shown a survival benefit using a combination of these treatments for nasopharyngeal carcinoma.
View More Related Trials
Frequently Asked Questions
Introduction to ebv
What are the top hospitals conducting ebv research?
Cutting-edge clinical trials aimed at tackling the complexities of Epstein-Barr virus (EBV) are being conducted at some of the top hospitals across North America. In Houston, Texas Children's Hospital leads the charge with an impressive 11 ongoing EBV trials and a total of 15 studies throughout its history. This renowned institution embarked on its first EBV trial back in 1993, setting a precedent for groundbreaking research into this viral infection that affects millions worldwide. Nearby, Houston Methodist Hospital is also making significant strides with eight active EBV trials and a noteworthy track record of 11 previous investigations since their initial study in 1993.
Venturing north to Toronto, Canada's Princess Margaret Cancer Centre has recently joined the forefront by delving into three active EBV trials—an exciting advancement given their relatively short history in researching this virus. Their pioneering work began just last year in 2021, demonstrating their commitment to unraveling the mysteries surrounding EBV and developing innovative treatment options.
Further east in Washington, D.C., Children's National Medical Center stands as a powerhouse for pediatric medicine and is actively engaged in three ongoing EBV clinical trials. Since conducting their inaugural trial in 2013, they have remained dedicated to understanding and combating this challenging viral infection specifically among young patients.
Finally, Roswell Park Comprehensive Cancer Center located in Buffalo contributes significantly to advancing our knowledge about EBV through three currently active clinical trials alongside three historical studies dating back to 2018 when they initiated their first exploration into this field.
These esteemed institutions exemplify the importance placed on finding effective treatments for individuals affected by Epstein-Barr virus infections. By relentlessly pursuing medical breakthroughs through rigorous research efforts on multiple fronts, they offer hope not only to those directly impacted but also potential solutions that could transform future healthcare practices globally
Which are the best cities for ebv clinical trials?
When it comes to EBV clinical trials, several cities emerge as top contenders for cutting-edge research. Houston, Texas leads the pack with 28 active trials investigating iCaspase9-transduced T cells, MABEL CTLs, and EBV-specific T cells. New york, New York follows closely behind with 15 ongoing studies focusing on tabelecleucel, Posoleucel (ALVR105), and Cisplatin. Atlanta, Georgia boasts 13 active trials exploring treatments like Cisplatin, Posoleucel (ALVR105), and tabelecleucel. Meanwhile, Boston, Massachusetts contributes to the field with 12 ongoing trials examining treatments such as Cisplatin and Virus Specific T-cell (VST) infusion. Lastly, Los Angeles California hosts ten active trials studying Virus Specific T-cell (VST) infusion alongside other potential breakthroughs in EBV treatment methods. These cities offer individuals battling EBV access to a diverse range of clinical trial options that may pave the way for improved care outcomes in the future.
Which are the top treatments for ebv being explored in clinical trials?
Clinical trials are shedding light on the top treatments currently being explored for EBV. Among them, Posoleucel (ALVR105) stands out with one active trial and two all-time trials dedicated to combating this virus since its listing in 2021. Another promising contender is Rapidly generated virus specific T (R-MVST) cells, which made its debut in 2022 and has already garnered attention with one active trial and one all-time EBV trial. Lastly, Epstein-Barr Virus Specific T-Lymphocytes have also shown promise with one ongoing trial and a strong start after being listed in 2020. These innovative treatment options offer hope for those affected by EBV as researchers continue their efforts to find effective solutions.
What are the most recent clinical trials for ebv?
Recent clinical trials have been making significant strides in the field of Epstein-Barr virus (EBV) research, offering hope for improved treatment options. Among these trials is an interventional study that combines both Phase 1 and Phase 2 investigations, demonstrating promising potential against EBV. Additionally, another trial focuses on the use of pembrolizumab to combat EBV, with encouraging results from its Phase 2 stage. Another notable study explores a specific treatment arm targeting EBV in its Phase 2 stage. These advancements mark important milestones in our ongoing fight against this challenging viral infection.
What ebv clinical trials were recently completed?
A noteworthy clinical trial focused on the treatment of EBV infection has reached a significant milestone. Sponsored by Viracta Therapeutics, Inc., the VRx-3996 trial was successfully completed in March 2018. This study represents an important step forward in our understanding and potential management of this challenging viral infection. While further research is necessary to build upon these findings, it highlights the dedication of scientists and researchers in their quest for innovative therapies against EBV.